Counterfeit Ozempic charges announced on September 29 concern an alleged scheme to sell fake pens through U.S. distributors. For someone holding a pen, the useful checks are its source and FDA's specific packaging warnings. A prescription and a familiar-looking box cannot settle the question by themselves.
What happened in the counterfeit Ozempic case
As of September 30, 2026, the day this article was written, FDA's announcement describes charges against two defendants. The release is dated September 29, 2026. The Justice Department's announcement, dated the same day, describes conspiracy and smuggling charges. Conspiracy means an alleged agreement to break the law. Smuggling means bringing goods across borders while evading customs rules.
According to the allegations, the defendants obtained counterfeit Ozempic from unauthorized sources in China between July 2023 and April 2024. The alleged fakes included packaging, package inserts, pen labels and needles intended to look authentic. Prosecutors say the products were sold to U.S. distributors.
FDA says court documents allege distribution continued after its December 2023 seizure and public warning. That is an allegation about past conduct, not a new finding about every pen being dispensed today.
An indictment is a formal accusation, not a conviction. Both defendants are presumed innocent unless proven guilty in court.
FDA's release says the alleged counterfeits were meant to deceive downstream customers, including pharmacies and patients. This reaches beyond anonymous websites: a pharmacy's own purchasing record matters too.
For a semaglutide prescription, product identity is the immediate question. Semaglutide is the drug ingredient; Ozempic is a branded product containing it. Our semaglutide and Ozempic explainer covers that distinction. The dispensing pharmacy needs to establish which product it supplied and where that product came from.
How to tell if an Ozempic pen is fake
The FDA counterfeit warning, marked “Content current as of: 12/05/2025,” lists three warnings involving 1 mg pens. A lot number identifies a production batch. A serial number identifies an individual package.
| Warning date | Lot number | Other identifying detail |
|---|---|---|
| December 5, 2025 | PAR1229 | On counterfeit pen labels, EXP/LOT sits to the left of the date and lot; authentic labels place it above them |
| April 14, 2025 | PAR0362 | Serial number begins with 51746517 |
| December 21, 2023 | NAR0074 | Serial number 430834149057 |
EXP/LOT marks the expiration date and batch number. The newer warnings matter because counterfeiters copied authentic lot numbers. The lot alone cannot establish authenticity.
These are specific clues, not a complete test of every possible counterfeit. A pen that doesn't match this table still needs a reliable source. FDA's counterfeit-medicine guide explains that fakes can contain the wrong ingredients or the wrong amount of medicine. Photos cannot establish what is inside a pen or whether its needle is sterile, meaning free of living germs.
FDA advises against using products matching its counterfeit details. A pharmacist can compare the pen and carton with the agency's photographs and ask the manufacturer to investigate. An online seller's reassurance is a weak substitute for that traceable check.
What a prescription route makes possible
FDA recommends a state-licensed pharmacy. Its Ozempic warning specifies a valid prescription, and Novo Nordisk advises pharmacies to use authorized distributors. These are two connected checks: the pharmacy's license and the source of its stock.
Useful questions for the pharmacy and prescribing service include:
- Who is the named prescriber, and how can they be reached? A product question and a symptom question may need different people.
- Which pharmacy dispensed this prescription, and where is its state license recorded? A business name on a website is only a starting point.
- Was this Ozempic obtained through an authorized distributor? A prescription does not authenticate stock acquired elsewhere.
- Can the pharmacy trace this lot and review the pen and carton together? The package and the device both matter.
- Who handles product complaints and contacts patients if a problem is found? There needs to be a reachable person and a dispensing record.
That record cannot prevent every problem. It gives the pharmacy a way to identify affected patients and respond. Our compounded medication recall guide explains how the pharmacy, medication and lot connect during a recall.
For prescribed compounded semaglutide, the preparation should be identified as the pharmacy's own medication. It should not be presented as an authentic Ozempic pen. The label, prescription and pharmacy record need to describe the same product.
What the charges do not mean
The charges do not turn every compounded semaglutide preparation into counterfeit Ozempic. A counterfeit pretends to be an authentic product. Compounding means a pharmacy prepares medication for a particular prescription.
Through Promise, semaglutide and tirzepatide are dispensed as compounded medications, which are different from an FDA-approved product: the formulations offered here are not FDA-approved. FDA explains that it does not review compounded drugs for safety, effectiveness or quality before marketing.
A licensed provider may still prescribe a compounded formulation when the clinical and legal conditions are met; that decision is between the patient and the doctor.
The criminal case concerns a particular alleged distribution scheme. It does not identify the contents of every suspicious pen or show that an individual patient's medication was involved. Authenticity questions belong with the dispensing pharmacy and manufacturer; treatment questions belong with the prescriber.
What testing can tell us about unknown products
In a 2024 JAMA Network Open investigation, researchers made purchases from six online sellers that did not require prescriptions. Only the three vial orders arrived; the three sellers advertising Ozempic pens never delivered and asked for extra “customs” payments. Each held 29% to 39% more semaglutide than its label stated (Ashraf and colleagues). That small sample shows why a label needs an accountable source. It cannot tell us how common counterfeits are.
As of September 30, 2026, the day this article was written, a newer study adds reports of suspected medicine problems. A study published April 29, 2026 in Frontiers in Pharmacology examined 234 reports involving suspected counterfeit semaglutide from 2018 through 2025. Low blood sugar was reported more often than in reports without counterfeit flags. The authors did not test each product, and these reports cannot establish a patient's chance of harm.
The counterfeit retatrutide report describes a separate wrong-ingredient investigation. A product name is a claim about the contents, not proof.
Tirzepatide is a different medicine a provider may consider for weight management. Changing drug names does not answer the sourcing question; its prescription and dispensing pharmacy still need to be clear.
What to watch next, and where to report a concern
The next meaningful updates are court decisions and any new FDA identification details. Charges alone do not establish guilt, and a future warning may identify different packaging or numbers.
Suspected counterfeit products can be reported through FDA's product-reporting portal. Reactions or product problems can go to MedWatch, FDA's safety-reporting program, and Novo Nordisk customer care at 1-800-727-6500, the contact FDA's counterfeit Ozempic warning lists for authenticity questions. The dispensing pharmacy and prescriber remain the contacts for the product in hand and any symptoms.
At Promise, a licensed provider reviews every request and not everyone qualifies.
